Cell therapy for cerebral ischemia using vascular endothelial growth factor-secreting cells

Tetsuro Shingo, Isao Date, Akimasa Yano, Kazuki Kobayashi, Akira Takeuchi, Takao Yasuhara, Takashi Ohmoto

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

To evaluate a potential neuroprotective role for vascular endothelial growth factor (VEGF) during ischemia, we grafted encapsulated VEGF-secreting cells into the brain parenchyma of a rat model of stroke. A genetically modified VEGF-secreting cell line (50–100 ng/106cells/day) was established, and when encapsulated, these cells produced VEGF in a continuous and stable fashion for at least 2 months (30–50 ng/capsule/day). Recombinant human VEGF was delivered into the rat striatum at approximately the same delivery rate as that observed by the encapsulated cells (35 or 70 ng/day) for 6 days using a mini-osmotic pump. Six days after infusion, host animals received transient middle cerebral artery occlusion by the intraluminal suture technique. We found that the infarct volume in the VEGF infusion group was reduced by approximately 40% compared with vehicle infusion group. Furthermore, VEGF infusion caused significantly increased cerebral angiogenesis in the ischemic brain. In the penumbra area, the number of apoptotic cells in the VEGF infusion group was decreased significantly compared with that in vehicle group. These data show that the administration of a low-dose of VEGF into the parenchyma has both angiogenic and neuroprotective effects in the ischemic brain. Encapsulation and the grafting of genetically modified VEGF-secreting cells may be considered as a potentially effective therapy for the treatment of stroke in the future.

Original languageEnglish
Pages (from-to)483-487
Number of pages5
JournalInternational Congress Series
Volume1252
Issue numberC
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Cell- and Tissue-Based Therapy
Brain Ischemia
Vascular Endothelial Growth Factor A
Brain
Stroke
Suture Techniques
Middle Cerebral Artery Infarction
Neuroprotective Agents
Capsules
Ischemia
Cell Count
Cell Line
Therapeutics

Keywords

  • Angiogenesis
  • Encapsulation
  • Neuroprotection
  • Transplantation
  • VEGF

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Cell therapy for cerebral ischemia using vascular endothelial growth factor-secreting cells. / Shingo, Tetsuro; Date, Isao; Yano, Akimasa; Kobayashi, Kazuki; Takeuchi, Akira; Yasuhara, Takao; Ohmoto, Takashi.

In: International Congress Series, Vol. 1252, No. C, 01.06.2003, p. 483-487.

Research output: Contribution to journalArticle

Shingo, Tetsuro ; Date, Isao ; Yano, Akimasa ; Kobayashi, Kazuki ; Takeuchi, Akira ; Yasuhara, Takao ; Ohmoto, Takashi. / Cell therapy for cerebral ischemia using vascular endothelial growth factor-secreting cells. In: International Congress Series. 2003 ; Vol. 1252, No. C. pp. 483-487.
@article{06bc2ad91c4347b78c754dcdef79061a,
title = "Cell therapy for cerebral ischemia using vascular endothelial growth factor-secreting cells",
abstract = "To evaluate a potential neuroprotective role for vascular endothelial growth factor (VEGF) during ischemia, we grafted encapsulated VEGF-secreting cells into the brain parenchyma of a rat model of stroke. A genetically modified VEGF-secreting cell line (50–100 ng/106cells/day) was established, and when encapsulated, these cells produced VEGF in a continuous and stable fashion for at least 2 months (30–50 ng/capsule/day). Recombinant human VEGF was delivered into the rat striatum at approximately the same delivery rate as that observed by the encapsulated cells (35 or 70 ng/day) for 6 days using a mini-osmotic pump. Six days after infusion, host animals received transient middle cerebral artery occlusion by the intraluminal suture technique. We found that the infarct volume in the VEGF infusion group was reduced by approximately 40{\%} compared with vehicle infusion group. Furthermore, VEGF infusion caused significantly increased cerebral angiogenesis in the ischemic brain. In the penumbra area, the number of apoptotic cells in the VEGF infusion group was decreased significantly compared with that in vehicle group. These data show that the administration of a low-dose of VEGF into the parenchyma has both angiogenic and neuroprotective effects in the ischemic brain. Encapsulation and the grafting of genetically modified VEGF-secreting cells may be considered as a potentially effective therapy for the treatment of stroke in the future.",
keywords = "Angiogenesis, Encapsulation, Neuroprotection, Transplantation, VEGF",
author = "Tetsuro Shingo and Isao Date and Akimasa Yano and Kazuki Kobayashi and Akira Takeuchi and Takao Yasuhara and Takashi Ohmoto",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0531-5131(03)00074-8",
language = "English",
volume = "1252",
pages = "483--487",
journal = "International Congress Series",
issn = "0531-5131",
publisher = "Elsevier BV",
number = "C",

}

TY - JOUR

T1 - Cell therapy for cerebral ischemia using vascular endothelial growth factor-secreting cells

AU - Shingo, Tetsuro

AU - Date, Isao

AU - Yano, Akimasa

AU - Kobayashi, Kazuki

AU - Takeuchi, Akira

AU - Yasuhara, Takao

AU - Ohmoto, Takashi

PY - 2003/6/1

Y1 - 2003/6/1

N2 - To evaluate a potential neuroprotective role for vascular endothelial growth factor (VEGF) during ischemia, we grafted encapsulated VEGF-secreting cells into the brain parenchyma of a rat model of stroke. A genetically modified VEGF-secreting cell line (50–100 ng/106cells/day) was established, and when encapsulated, these cells produced VEGF in a continuous and stable fashion for at least 2 months (30–50 ng/capsule/day). Recombinant human VEGF was delivered into the rat striatum at approximately the same delivery rate as that observed by the encapsulated cells (35 or 70 ng/day) for 6 days using a mini-osmotic pump. Six days after infusion, host animals received transient middle cerebral artery occlusion by the intraluminal suture technique. We found that the infarct volume in the VEGF infusion group was reduced by approximately 40% compared with vehicle infusion group. Furthermore, VEGF infusion caused significantly increased cerebral angiogenesis in the ischemic brain. In the penumbra area, the number of apoptotic cells in the VEGF infusion group was decreased significantly compared with that in vehicle group. These data show that the administration of a low-dose of VEGF into the parenchyma has both angiogenic and neuroprotective effects in the ischemic brain. Encapsulation and the grafting of genetically modified VEGF-secreting cells may be considered as a potentially effective therapy for the treatment of stroke in the future.

AB - To evaluate a potential neuroprotective role for vascular endothelial growth factor (VEGF) during ischemia, we grafted encapsulated VEGF-secreting cells into the brain parenchyma of a rat model of stroke. A genetically modified VEGF-secreting cell line (50–100 ng/106cells/day) was established, and when encapsulated, these cells produced VEGF in a continuous and stable fashion for at least 2 months (30–50 ng/capsule/day). Recombinant human VEGF was delivered into the rat striatum at approximately the same delivery rate as that observed by the encapsulated cells (35 or 70 ng/day) for 6 days using a mini-osmotic pump. Six days after infusion, host animals received transient middle cerebral artery occlusion by the intraluminal suture technique. We found that the infarct volume in the VEGF infusion group was reduced by approximately 40% compared with vehicle infusion group. Furthermore, VEGF infusion caused significantly increased cerebral angiogenesis in the ischemic brain. In the penumbra area, the number of apoptotic cells in the VEGF infusion group was decreased significantly compared with that in vehicle group. These data show that the administration of a low-dose of VEGF into the parenchyma has both angiogenic and neuroprotective effects in the ischemic brain. Encapsulation and the grafting of genetically modified VEGF-secreting cells may be considered as a potentially effective therapy for the treatment of stroke in the future.

KW - Angiogenesis

KW - Encapsulation

KW - Neuroprotection

KW - Transplantation

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=34248399454&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248399454&partnerID=8YFLogxK

U2 - 10.1016/S0531-5131(03)00074-8

DO - 10.1016/S0531-5131(03)00074-8

M3 - Article

AN - SCOPUS:34248399454

VL - 1252

SP - 483

EP - 487

JO - International Congress Series

JF - International Congress Series

SN - 0531-5131

IS - C

ER -